Biocon arm expands oncology portfolio after USFDA nod for cancer drug Jobevne

Share it

Biocon Share Price | Jobevne is a recombinant humanised monoclonal antibody that is used to treat several types of cancer. It is a biosimilar to the reference product Avastine (bevacizumab), Biocon said.

Leave a Comment

Your email address will not be published. Required fields are marked *